Insmed (NASDAQ:INSM) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Insmed (NASDAQ:INSM) released its earnings results on Thursday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company had revenue of $524.43 million during the quarter, compared to the consensus estimate of $499.06 million. During the same quarter in the previous year, the business posted ($1.75) EPS. The firm’s quarterly revenue was up 268.4% on a year-over-year basis.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI’s launch continues to materially outperform expectations: Third-quarter revenue reached $400.1 million, up 29% sequentially, and the product surpassed $1 billion in its first four full quarters. Insmed raised 2026 BRINSUPRI guidance to $1.35 billion-$1.4 billion.
• ARIKAYCE also delivered steady growth and faces a major potential market expansion. Third-quarter revenue rose 9% year over year to $124.4 million, prompting higher 2026 guidance of $460 million-$470 million; FDA priority review for a broader MAC lung disease label has a January 28, 2027 action date.
• Insmed expects to reach cash-flow positivity in 2027. The company ended the quarter with approximately $1.1 billion in cash, while management said BRINSUPRI’s growth should improve operating leverage even as investments continue across the pipeline.
• The long-term pipeline remains a significant growth driver, led by TPIP. TPIP’s four Phase 3 studies are advancing, with the PH-ILD trial more than 35% enrolled and ahead of schedule; management estimates more than $6 billion in peak sales potential, although approvals and clinical outcomes remain uncertain.
• Insmed is pursuing a large but still unquantified expansion of BRINSUPRI’s opportunity in COPD and asthma patients with undiagnosed comorbid bronchiectasis. AI diagnostic tools, imaging studies, physician education and other initiatives are underway, with initial findings expected around mid-2027; management characterized the opportunity as substantial but acknowledged that adoption will take time.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $14.32 during midday trading on Thursday, reaching $111.30. 8,572,547 shares of the company were exchanged, compared to its average volume of 2,969,150. The business’s fifty day moving average is $113.29 and its two-hundred day moving average is $126.28. Insmed has a one year low of $90.39 and a one year high of $212.75. The stock has a market cap of $24.31 billion, a PE ratio of -27.05 and a beta of 0.83. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insider Buying and Selling

In other news, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David R. Brennan sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is currently owned by company insiders.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raised revenue outlook: Insmed increased its 2026 revenue guidance for BRINSUPRI to $1.35 billion–$1.40 billion and for ARIKAYCE to $460 million–$470 million. The company also launched BRINSUPRI in Japan, expanding the product’s commercial opportunity. Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Revenue growth exceeded expectations: Third-quarter revenue rose 268.4% year over year to $524.4 million, above the roughly $499.1 million analyst consensus. BRINSUPRI generated $400.1 million, up 29% from the prior quarter, while ARIKAYCE revenue increased 9% year over year to $124.4 million. Insmed Raises FY26 Revenue Outlook for BRINSUPRI and ARIKAYCE
• Positive Sentiment: Quarterly loss narrowed: Insmed reported a loss of $0.46 per share, improving from a $1.75 loss a year earlier. Although the result missed analyst expectations, the year-over-year improvement and accelerating product revenue supported the bullish reaction. Insmed Inc Q3 Loss Narrows
• Neutral Sentiment: Unusually active options trading: Traders purchased 7,706 call options, 121% above the average volume of 3,483 contracts. The activity suggests increased bullish speculation, but options volume alone does not confirm a sustained change in investor expectations.
• Negative Sentiment: EPS missed estimates: The quarterly loss of $0.46 per share was wider than the consensus loss of $0.39, highlighting continuing profitability risk for the biotechnology company. Insmed Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: Price target reduction: Raymond James lowered its Insmed price target from $187 to $173, potentially limiting sentiment even though the revised target remains above the current trading range. Raymond James Cuts Target for Insmed

Analyst Ratings Changes

Several analysts have commented on INSM shares. UBS Group reiterated a “buy” rating on shares of Insmed in a research report on Thursday, October 8th. Wells Fargo & Company boosted their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Morgan Stanley lowered their price target on Insmed from $218.00 to $213.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 21st. Roth Capital reaffirmed a “buy” rating and set a $198.00 price target (down from $212.00) on shares of Insmed in a research report on Tuesday, September 15th. Finally, Bank of America reiterated a “buy” rating and issued a $207.00 price target on shares of Insmed in a research note on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $197.26.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.